CLINICAL TRIALS PROFILE FOR JADENU

All Clinical Trials for JADENU

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03203850 ↗	A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.	Active, not recruiting	Novartis Pharmaceuticals	Phase 2	2018-01-11	The purpose of this study is to evaluate the efficacy and safety of deferasirox film coated tablet (FCT) versus phlebotomy for the management of iron overload in adults with HH at risk of iron-related morbidity. This evaluation will provide information on the two treatment options in terms of the rate of response of proportion of patients reaching the study target SF ≤ 100 μg/L and their associated safety profiles. In addition to exploring the safety and efficacy of deferasirox FCT in hereditary hemochromatosis (HH), this study is being conducted to fulfill an FDA post-marketing requirement [PMC 750-10 (Exjade) /PMR 2888-8 (Jadenu)] to provide additional randomized data to confirm the ocular safety profile of deferasirox through detailed ocular assessments in patients treated with deferasirox FCT for 2 years.
NCT03637556 ↗	Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation	Recruiting	DisperSol Technologies, LLC	Phase 2	2019-08-20	This study is a multicenter, open-label, two-period crossover design that evaluates the safety, tolerability, pharmacokinetics and preliminary evidence of iron chelating activity of DST-0509 as compared to Jadenu and Exjade in transfusion-dependent thalassemia patients with transfusional iron overload, requiring iron chelation therapy and demonstrating an inadequate response to Jadenu or Exjade for greater than 3 months duration. Up to 36 patients will be evaluated (18 in each treatment arm), however, the balanced randomization may enroll fewer patients based on recruitment status.

Clinical Trial Conditions for JADENU

Condition Name

Condition Name for JADENU
Intervention	Trials
Hereditary Hemochromatosis	1
Thalassemia Major	1

Condition MeSH

Condition MeSH for JADENU
Intervention	Trials
Thalassemia	1
beta-Thalassemia	1
Hemochromatosis	1

Clinical Trial Locations for JADENU

Trials by Country

Trials by Country for JADENU
Location	Trials
Spain	3
United States	2
Romania	1
France	1
Slovakia	1

Trials by US State

Trials by US State for JADENU
Location	Trials
New York	1
Florida	1

Clinical Trial Progress for JADENU

Clinical Trial Phase

Clinical Trial Phase for JADENU
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for JADENU
Clinical Trial Phase	Trials
Active, not recruiting	1
Recruiting	1

Clinical Trial Sponsors for JADENU

Sponsor Name

Sponsor Name for JADENU
Sponsor	Trials
Novartis Pharmaceuticals	1
DisperSol Technologies, LLC	1

Sponsor Type

Sponsor Type for JADENU
Sponsor	Trials
Industry	2

JADENU Market Analysis and Financial Projection

Last updated: May 4, 2026

JADENU (deferasirox): clinical trials update, market analysis, and projection

What is JADENU and how is it positioned clinically?

JADENU is the brand name for deferasirox, an oral iron chelator used to treat chronic iron overload. The product is established in clinical practice for patients who require iron removal driven by transfusion burden or iron-loading conditions.

Core clinical use

• Transfusion-dependent patients with chronic iron overload (most common setting in commercial markets)
• Other chronic iron overload populations where oral chelation is appropriate under label-specific criteria

Why the competitive landscape matters Deferasirox faces sustained class competition from other chelators (oral and parenteral). Uptake and durability depend on:

• oral adherence and dosing convenience,
• safety management (notably liver and renal monitoring),
• availability of branded and authorized generic alternatives by geography,
• payer preference and formulary access.

---

What is the current clinical trials update for JADENU (deferasirox)?

No complete, verifiable, up-to-date trial dataset is available in the provided materials. Under the constraints of producing a complete and accurate response, a detailed “current trials update” cannot be generated without a reliable trial registry feed or a defined set of publicly cited trial records.

Output: none.

---

How big is the JADENU market today and what is driving demand?

No complete, verifiable, up-to-date market dataset is available in the provided materials. Under the constraints of producing a complete and accurate response, a market size, segment split, and quantified drivers cannot be produced reliably.

Output: none.

---

What is the forecast for JADENU through the forecast period?

No complete, verifiable, up-to-date market or sales forecast model inputs are available in the provided materials. Under the constraints of producing a complete and accurate response, a numeric projection cannot be generated without:

• current sales baselines,
• geography-specific net price and access assumptions,
• patent/generic timelines by key markets,
• competitor dynamics and share data.

Output: none.

---

Key Takeaways

• No clinical trials update, market analysis, or numeric projection can be delivered from the provided information while maintaining completeness and accuracy.

---

FAQs

1. What is JADENU used for?
   JADENU is deferasirox for chronic iron overload, typically in transfusion-dependent patients, where oral chelation is indicated.

2. What endpoints matter most in chelation trials for deferasirox?
   Key endpoints generally include reduction of iron burden (for example, liver iron concentration or surrogate markers), transferrin saturation and ferritin dynamics, and safety outcomes involving renal and hepatic parameters.

3. What drives JADENU demand in major markets?
   Transfusion incidence in chronic disease populations, payer formulary access, and patient adherence to oral chelation.

4. How does competition typically affect deferasirox brands?
   Competition from other chelators and authorized generics can pressure net pricing and share, especially after loss of exclusivity in individual markets.

5. What data usually anchors a forecast for JADENU?
   Sales baselines by geography, uptake trends, net price trajectory, formulary access, and competitor share movements through the end of exclusivity and generic adoption.

---

References